| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 156 |
| 1 | CARBOPLATIN | 85 |
| 2 | NIVOLUMAB | 78 |
| 3 | IPILIMUMAB | 67 |
| 4 | PACLITAXEL | 58 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 57 |
| 6 | CYCLOPHOSPHAMIDE | 28 |
| 7 | CYCLOPHOSPHAMIDE FOR INJECTION | 28 |
| 8 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 28 |
| 9 | CISPLATIN | 17 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | FOSNETUPITANT AND PALONOSETRON | 6 | 0.0050 |
| 1 | NETUPITANT AND PALONOSETRON | 6 | 0.0050 |
| 2 | PEGFILGRASTIM-JMDB | 2 | 0.0044 |
| 3 | PLATINUM | 1 | 0.0019 |
| 4 | IPILIMUMAB | 67 | 0.0015 |
| 5 | PEMBROLIZUMAB | 156 | 0.0014 |
| 6 | EPIRUBICIN HYDROCHLORIDE | 7 | 0.0011 |
| 7 | SOTORASIB | 3 | 0.0009 |
| 8 | NIVOLUMAB | 78 | 0.0008 |
| 9 | CARBOPLATIN | 85 | 0.0007 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 239 |
| 1 | Platinum-based Drug [EPC] | 106 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 67 |
| 3 | Microtubule Inhibitor [EPC] | 59 |
| 4 | Alkylating Drug [EPC] | 29 |
| 5 | Corticosteroid [EPC] | 17 |
| 6 | Factor Xa Inhibitor [EPC] | 14 |
| 7 | Kinase Inhibitor [EPC] | 14 |
| 8 | Nonsteroidal Anti-inflammatory Drug [EPC] | 12 |
| 9 | Angiotensin Converting Enzyme Inhibitor [EPC] | 11 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 239 | 0.0024 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 67 | 0.0014 |
| 2 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 10 | 0.0011 |
| 3 | Platinum-based Drug [EPC] | 106 | 0.0004 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 8 | 0.0004 |
| 5 | Microtubule Inhibitor [EPC] | 59 | 0.0004 |
| 6 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |
| 7 | Thyroid Hormone Synthesis Inhibitor [EPC] | 3 | 0.0003 |
| 8 | Chloride Channel Activator [EPC] | 2 | 0.0002 |
| 9 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 3 | 0.0001 |